With our eSHAPE technology we obtain validated data on the RNA secondary structure of a target gene, outperforming predictive algorithms that use the sequence alone. This structure information can be used to select target regions that are accessible and free of protein regulation.

With our miR-eCLIP+ technology, we directly measure where and how miRNAs bind across the transcriptome. This information can be used to identify competing miRNAs for siRNA treatments or to select miRNAs to target for anti-miRs.

Our miR-eCLIP+ technology directly measures both miRNA and siRNA binding, making it a powerful tool for examining where and how off-target activity is occurring. Off-target binding can occur through both seed-based binding and compensatory binding, and our technology distinguishes between these for siRNA optimization.

Off-target effects are not limited to just the transcriptome, the translatome can be affected as well. With our eRibo Pro technology we measure both RNA expression (RNA-Seq) and translation (ribosome profiling), providing a more complete view of how a therapeutic affects cellular activity.

With our eSHAPE technology we can obtain validated information on the RNA secondary structure of a target gene. This structure information can be used to select drug candidates that target druggable pockets that are free of competition from proteins and miRNAs. It can also be used to directly measure where small molecules bind to a target RNA.

With different diseases, a given gene can use different UTRs (regulatory regions outside the coding sequence). Our End-Seq technology directly identifies where UTRs are located, supporting the identification of druggable regions specific to the disease.

RNA-binding proteins have been implicated in ASO activity and are frequent targets for small molecules and aptamers. With our RBP-eCLIP technology, we identify where a given protein binds across the transcriptome revealing information on potential proteins to block or mimic with small molecule drugs and to confirm protein activity for ASO efficacy.

With eRibo Pro we directly measure changes in RNA expression (RNA-Seq) and translation (ribosome profiling), allowing for a comprehensive view of how a therapeutic affects cellular activity.

With our eSHAPE technology we can obtain validated measurements of the RNA secondary structure of a gene in different contexts, including directly after in vitro transcription or within the context of the cell.

Within the same assay, eRibo Pro provides information on RNA expression (RNA-Seq) and translation (ribosome profiling). With this information, researchers can gain mechanistic insights into how an experimental change affects a system across multiple dimensions.

miRNAs are key regulators of RNA stability and translation. With our miR-eCLIP+ assay, we directly determine where and how miRNAs bind across the transcriptome. This provides unparalleled insights into miRNA biology and regulation across cell lines and tissues.

All RNAs in the cell are bound by proteins that regulate their stability, translation, and localization. With RBP-eCLIP, researchers can determine exactly where a given RNA-binding protein acts including what gene features it binds to and what sequence motifs it recognizes.

With different diseases, a given gene can use different UTRs (untranslated regulatory regions outside the coding sequence). Our End-Seq technology directly identifies where UTRs start and end, providing a fuller understanding of how genes are regulated in a given condition.

Complexes of RNA-binding proteins write and remove methylation on RNA transcripts, and this methylation has been implicated in a number of critical biological processes. With m6A-eCLIP, we provide per-base resolution of where methylated adenosines are located across the transcriptome.